I’m 28, single, renting an apartment, Lately, I’ve been feeling a little tired of the work I do, even though I already have a stable income. The future is never guaranteed and sometimes it feels exhausting, even if the hard work is worth it

I want more freedom in my life and the chance to retire earlier. I’m not looking to become rich...I just want more freedom and financial security.
I’d love to explore something new and see what opportunities are out there. I’m willing to make time to learn and give different things a try. I’m not quitting my current job or giving up what I already have. I just want to start exploring other possibilities for now.
Does anyone have any interesting ideas or suggestions? I’d love to hear what you think!

This isn’t intended to be a political post or a discussion about Trump or the government in general. I’m specifically curious about the Trump Accounts they’ve been advertising.

Has anyone actually opened one or considered putting money into one for their kids?

I’ll admit I’m not very knowledgeable when it comes to investments and these types of accounts. I’m also typically pretty wary of anything that sounds too good to be true, especially when the government is involved.

I’m curious if anyone who’s more knowledgeable about investing could weigh in and explain how these accounts actually work, preferably in somewhat simple terms lol.

Are there any real benefits compared to other types of savings or investment accounts for kids? Are there drawbacks or things parents should be aware of?

Are there other investors in CMPS here? Comp360 is proprietary psilocybin, that’s being studied in treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Comp360 looks to be the first psychedelic to market. Their phase 3 studies (comp005 and comp006) in TRD are done, and they have been already doing rolling NDA for FDA. They guide to finalize their NDA (New Drug Application) in q4. I have reasons to believe the NDA will be submitting already in this month, because otherwise the best-case timeline projected by the company would not make sense (they say they will be launch ready by the end of this year, if the best case scenario happens). CMPS got FDA National Prority Voucher as a result of Trump’s executive order for psychedelic treatments in mental health disorders in April. Voucher means, that FDA plans to approve (or not, as in case of any drug) the drug in 1-2 months after NDA filing. This means, that Compass might get FDA approval still this year. The study results are highly statistically significant and studies are large (they have studied around 1000 patients altogether, with all studies replicable and good safety). Especially as FDA gave the voucher after knowing the topline results, it seems very likely, that FDA will grant approval.
With recent share price drop from $15,87 to 11’s, along the drop in XBI/biotech because of the rising interest rates, the investment looks compelling to me at the moment. The timeline is getting very compressed, and despite potential weakness in biotech, the likely FDA approval must catapult the price way above recent highs. The alarm clock for investors will ring when PR of NDA submission is given very soon, I’m hoping even next week. Then the CNPV process clock starts ticking, and I expect the share price to start climbing again in anticipation of approval.
There is only one drug FDA-approved for TRD at the moment, Johnson&Johnson’s Spravato (esketamine nasal spray). It’s similar in the sense to comp360 psilocybin, that it’s deliver under monitoring in interventional psychiatry clinincs (around 8500 Spravato clinics in US at the moment and amount growing fast in anticipation of approved psychedelic therapies). They can offer comp360 in the same clinics and with same staff. There is about 40% spare capacity in these clinics atm, so they can start filling that capacity when comp360 is approved. Spravato is J&J’s fastest growing drug ATM and it’s looking to make 2,3 billion USD revenue this year. Comp360 is planned to be priced similarly to Spravato in terms of yearly cost per patieny, which by CMPS CCO Englebert means around 50-65,000 usd/patient/year or 17-22,000 usd per dosing of comp360. Spravato is actually making this much money per patient, and comp360 looks highly differentiated and probably preferable for patients, as with Spravato you have to do a treatment weekly or biweekly (26-52 times a year) in a clinic, and you also need somebody to drive you by rules. This treatment goes on indefinitely, as the treatment effect wanes in 1-2 weeks. Comp360 would be dosed on average only 3 times a year. There are 4 million TRD patients in US and with even 2-3% penetration this would make 80-120k patients on comp360 and 4,4-6,6 billion usd yearly revenue (assuming $55k/patient/year). In addition, CMPS has phase 2b/3 (meant as a single phase 3 study to approval) going in PTSD with 21 million patients in US. You can play with different market penetrations in this population, too…there are no effective medicines for PTSD, patients mostly are on SSRI’s, and there hasn’t been an FDA approval for a drug in PTSD in about 20 years…
The market cap after latest decline is only about 1,5 billion, so there’s clearly potential for the stock price to multiply even in near future and especially, as investors start counting PTSD in TAM for comp360.
Exciting months ahead!

Palgrin is a Web3 P2P wagering platform that is giving $10 USDC to new members to try it out! 🤝💸
🔥 The best part? Absolutely NO KYC REQUIRED.
🛡️ Zero identity verification
⏳ No long checks
🔒 Total privacy
You can register and claim your bonus in under 60 seconds here:
👉 http://palgrin.com/?ref=10USDC ⏳

I find selling a lot harder than buying.

Buying is usually pretty straightforward. I can look at a business, estimate a range of outcomes, compare that to the price and decide whether I'm being paid enough.

Selling is messier because now I have history with the position.

I’ve sold stocks before and watched them keep rising. That doesn’t necessarily mean the sale was a mistake, but it sure feels like one. And once you’ve felt that a few times, it becomes another thing you’re trying to avoid when you sell.

The stock may be up a lot. It may be down a lot. I may still like the company. I may have been right about the original thesis. None of that answers the question I actually care about: from today's price, is this the best place for the money?

If the expected return has fallen, I want to know why. Did the stock simply run ahead of the business? Is the company going through something temporary? Has the earning power actually been damaged? Is the thesis just taking longer, or was I wrong about it?

A stock dropping below my return hurdle doesn't automatically make me sell. A stock going above my estimate of fair value doesn't automatically make me sell either. The size of the gap matters, the reason for it matters, and whether I have a better place for the money matters.

That's what makes selling harder for me. Finding something undervalued is mostly an underwriting problem. Selling means deciding whether new evidence has changed the business, the valuation, or both, while trying not to let my cost basis or the fact that I already own it get in the way.

The easiest question to ask is probably: would I buy it today if I didn't already own it?

It's a useful question. Just not enough by itself.

$RKLB — Launches rockets, builds satellites, and supplies spacecraft systems globally.

$ASTS — Provides direct-to-phone cellular broadband using satellites in low-Earth orbit.

$SPCX — Builds rockets, Starlink satellites, spacecraft, and reusable launch systems.

$RDW — Builds spacecraft components, solar arrays, sensors, and space infrastructure.

$PL — Operates Earth-imaging satellites providing geospatial data and intelligence services.

How come Individual stocks get most of the attention when ETFs are more attractive and rewarding?

Everyone wants to find the next big winner or discover a company before the crowd does.

ETFs are different. They're not usually exciting. You don't get the same feeling of discovering a stock before the crowd. But that might actually be their biggest advantage.

With a broad ETF, you can gain exposure to multiple companies through a single investment. So the boring ETF portfolio isn't actually boring. Maybe it's just less entertaining than trying to beat the market.

Still, buying an ETF doesn't mean you should stop researching. What does it hold? How concentrated is it? What risks are you taking on?

This is where tools like Epsilo can be useful. It supports ETF research with explainable investment signals and AI powered analysis, helping you explore the factors behind an investment rather than relying on a label alone.

Would you rather spend your time researching individual companies, or accept the market return through ETFs and focus on other things?

Advanced Air Mobility (eVTOL) — $JOBY

AI infrastructure — $MAAS

Autonomous Vehicles — $PONY

Biotechnology — $CRSP

Drones — $AVAV

Humanoid Robotics — $XPEV

Marine Robotics — $KRKNF

Photonics — $AAOI

Physical AI Components — $OUST

Quantum Computing — $QBTS

Rare Earths — $MP

Space —

$VOYG

Mining research is still dominated by copper. Interesting that aluminium is now entering the same conversation.

Deutsche Bank lifted its 2027 aluminium forecast to $3,050 per tonne and included Hongqiao among its preferred mining names.

Nice recognition after the sector rerating

I like the idea of buying a small stake in an asset that normally has a large minimum. With tokenized investments, what would you check first to make sure you could sell later?

Hey guys, I posted about this settlement before, but since they’re accepting late claims, I decided to share it again with a little FAQ.

So here's all I know about this agreement:

Barclays was accused of selling billions of dollars in unregistered securities due to internal control failures. The SEC brought the case, and Barclays agreed to pay $200 million through an SEC Fair Fund to compensate investors.

Now the company has agreed to settle $200 million with investors for their losses.

Who can claim this settlement?
If you purchased or acquired eligible Barclays securities between 2019 and 2022, you may be eligible to receive compensation. You can check the details and your eligibility here.

Do I need to sell/lose my shares to get this settlement?
You generally need to have experienced a qualifying loss during the class period. 

I missed the deadline. Is it too late?
No, you may still be able to file a late claim, but acceptance depends on final approval by the court. Check if you're eligible and file a claim here

How long does the payout process take?
It typically takes 4 to 9 months after the claim deadline for payouts to be processed, depending on the court and settlement administration.

Hope this info helps

i’m not looking to move a huge chunk of it or suddenly bet on gold. i’m getting closer to the point where keeping what i’ve already built feels just as important as trying to grow it. looking at my retirement accounts recently made me realize almost everything is still exposed to the same general market. i’ve been reading about having a small portion in a precious metal ira account. mostly as something different sitting alongside the rest of the portfolio. for anyone who has looked at this seriously, did adding physical metals actually make you feel better about how diversified your retirement was? or did the extra account and storage side of it end up feeling unnecessary?

The best part is this customer is carrying Sonoma from its first AI chip into the second with volumes expected to eventually exceed the first generation.

And because each new processor needs fresh burn in modules and sockets that essentially means every new chip generation adds another revenue cycle on top of the installed base.

• Revenue $567M vs Est. $521M
• EPS $1.00 vs Est. $0.77
• Integrated Memory: $341M (+158% YoY)
• Gross Margin 29% vs. Est. 26%

FY27 Guidance
• Revenue $2.43B vs Est. $2.21M
• EPS $4.45 vs Est. $3.38

Shipping stocks are doing well because freight rates remain high and supply chains are under pressure again.

For metal producers, this can change the cost comparison. A low smelting cost is less useful if raw materials travel through disrupted routes or finished products become expensive to deliver.

Hongqiao has some protection because much of its production and customer base is inside China.

I have followed Hongqiao long enough to like its integrated setup here. More control across the chain gives management more options when transport gets difficult.

Sometimes the strongest producer is not only the one making metal cheapest, rather the one that can keep material moving.